<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02389881</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-058-1002</org_study_id>
    <secondary_id>U1111-1165-3644</secondary_id>
    <nct_id>NCT02389881</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants</brief_title>
  <official_title>A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects After Multiple Oral Doses of TAK-058</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of
      multiple doses of TAK-058 in healthy non-elderly and elderly participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is TAK-058, which is under evaluation for the treatment
      of schizophrenia.

      This study will enroll approximately 32 healthy non-elderly and 8 healthy elderly
      participants. Participants will be randomly assigned (by chance, like flipping a coin) to one
      of the five treatment groups—which will remain undisclosed to the patient and study doctor
      during the study (unless there is an urgent medical need):

        -  Cohort 1 Non-elderly Healthy: TAK-058 25 mg

        -  Cohort 2 Non-elderly Healthy: TAK-058 75 mg

        -  Cohort 3 Non-elderly Healthy: TAK-058 150 mg

        -  Cohort 4 Elderly Healthy: TAK-058 25 mg

        -  Cohort 5 Non-elderly Healthy: TAK-058 300 mg

        -  Cohort 1-4 Non Elderly Placebo (dummy inactive solution) - this is an oral solution that
           looks like the study drug but has no active ingredient.

        -  Cohort 5 Elderly Placebo This single-center trial will be conducted in the United
           States. The overall time to participate in this study is 40 days if assigned to Cohort 1
           to 4. Participants will be confined to the clinic for 12 days, and will be contacted by
           telephone 11 and 30 days after last dose of study drug for a follow-up assessment (Days
           21 and 40).

      The overall time to participate in this study is 14 days if assigned to Cohort 5.
      Participants will be confined to the clinic for 4 days, and will be contacted by telephone 14
      days after last dose of study drug for a follow-up assessment (Day 14).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event</measure>
    <time_frame>Cohorts 1-4 Day 1 to Day 40; Cohort 5 Day 1 to Day 14</time_frame>
    <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post-Dose</measure>
    <time_frame>Cohorts 1-4 Day 1 to Day 40; Cohort 5 Day 1 to Day 14</time_frame>
    <description>The percentage of participants with any markedly abnormal standard safety laboratory values (chemistry and hematology) collected throughout study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Signs at Least Once Post-Dose</measure>
    <time_frame>Cohorts 1-4 Day 1 to Day 40; Cohort 5 Day 1 to Day 14</time_frame>
    <description>The percentage of participants with any markedly abnormal standard vital sign values collected throughout study. Vital signs included blood pressure (after 5 minutes supine and at 1 and 3 minutes after standing), pulse and oral temperature.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Cmax: Maximum Observed Plasma Concentration for TAK-058</measure>
    <time_frame>Day 1 predose and at multiple time points (up to 72 hours) postdose, and Day 10 predose and at multiple time points (up to 24 hours) postdose</time_frame>
    <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-058</measure>
    <time_frame>Day 1 predose and at multiple time points (up to 72 hours) postdose</time_frame>
    <description>AUClast is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean AUC24: Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-058</measure>
    <time_frame>Day 1 predose and at multiple time points (up to 24 hours) postdose</time_frame>
    <description>AUC24 is measure of area under the curve from time 0 to 24 hours postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-058</measure>
    <time_frame>Day 10 predose and at multiple time points (up to 24 hours) postdose</time_frame>
    <description>Area under the plasma concentration-time curve during a dosing interval, where tau (τ) is the length of the dosing interval.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Non-elderly Healthy: TAK-058 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Non-elderly Healthy: TAK-058 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-058 75 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 Non-elderly Healthy: TAK-058 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-058 150 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 Elderly Healthy: TAK-058 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in elderly healthy participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 Non-elderly Healthy: TAK-058 300 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-058 300 mg solution, orally, once daily on Day 1, in non-elderly healthy participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohorts 1, 2, 3 and 5 Non-elderly Healthy: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10 (Cohorts 1, 2 and 3), or TAK-058 placebo-matching solution, orally, once on Day 1 (Cohort 5), in non-elderly healthy participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 Elderly Healthy: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-058</intervention_name>
    <description>TAK-058 Solution</description>
    <arm_group_label>Cohort 1 Non-elderly Healthy: TAK-058 25 mg</arm_group_label>
    <arm_group_label>Cohort 2 Non-elderly Healthy: TAK-058 75 mg</arm_group_label>
    <arm_group_label>Cohort 3 Non-elderly Healthy: TAK-058 150 mg</arm_group_label>
    <arm_group_label>Cohort 4 Elderly Healthy: TAK-058 25 mg</arm_group_label>
    <arm_group_label>Cohort 5 Non-elderly Healthy: TAK-058 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-058 Placebo</intervention_name>
    <description>TAK-058 placebo-matching solution</description>
    <arm_group_label>Cohorts 1, 2, 3 and 5 Non-elderly Healthy: Placebo</arm_group_label>
    <arm_group_label>Cohort 4 Elderly Healthy: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages for this study are 18 to 60 years for non-elderly and 18 to 65 years for elderly.

          -  A male participant who is nonsterilized and sexually active with a female partner of
             childbearing potential agrees to use adequate contraception from signing of informed
             consent throughout the duration of the study and for 12 weeks after last dose.

          -  A female participant with no childbearing potential, which is defined as the subject
             has been surgically sterilized (hysterectomy, bilateral oophorectomy or tubal
             ligation) or who are postmenopausal (defined as continuous amenorrhea of at least 2
             years and follicle-stimulating hormone [FSH]&gt;40 IU/L).

          -  Weighs at least 45 kg (99 lbs) and has a body mass index (BMI) between 18.0 and 30.0
             kg/m^2, inclusive at Screening.

        Exclusion Criteria:

          -  Has received any investigational compound within 30 days prior to the first dose of
             study medication.

          -  Has received TAK-058 in a previous clinical study.

          -  Is an immediate family member, study site employee, or is in a dependent relationship
             with a study site employee who is involved in the conduct of this study (eg, spouse,
             parent, child, sibling) or may consent under duress.

          -  Has a known hypersensitivity to any component of the formulation of TAK-058.

          -  Has a positive urine drug result for drugs of abuse at Screening or Check-in (Day -1).

          -  Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol
             abuse within 6 months prior to the Screening Visit or is unwilling to agree to abstain
             from alcohol and drugs throughout the study.

          -  Female participants of childbearing potential (premenopausal, non-sterilized), or has
             a positive pregnancy test.

          -  Male participants that intend to donate sperm during the course of this study or for
             12 weeks thereafter.

          -  Has evidence of current cardiovascular, central nervous system, hepatic, hematopoietic
             disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy,
             asthma hypoxemia, hypertension, seizures, or allergic skin rash. There is any finding
             in the subject's medical history, physical examination, or safety laboratory tests
             giving reasonable suspicion of a disease that would contraindicate taking TAK-058, or
             a similar drug in the same class, or that might interfere with the conduct of the
             study. This includes, but is not limited to, peptic ulcer disease, seizure disorders
             and cardiac arrhythmias.

          -  Has previously had a seizure or convulsion (lifetime), including absence seizure and
             febrile convulsion.

          -  Has current or recent (within 6 months) gastrointestinal disease that would be
             expected to influence the absorption of drugs (ie, a history of malabsorption, any
             surgical intervention known to impact absorption [eg, bariatric surgery or bowel
             resection], esophageal reflux, peptic ulcer disease, erosive esophagitis, or frequent
             [more than once per week] occurrence of heartburn).

          -  Has a history of cancer or other malignancy, except basal cell carcinoma that has been
             in remission for at least 5 years prior to Day 1.

          -  Has a positive test result for hepatitis B surface antigen (HBsAg), antibody to
             hepatitis C virus (anti-HCV) or a known history of human immunodeficiency virus
             infection at Screening.

          -  Has poor peripheral venous access.

          -  Has donated or lost 450 mL or more of his or her blood volume (including
             plasmapheresis), or had a transfusion of any blood product within 45 days prior to Day
             1.

          -  Has a Screening or Check-in (Day -1) abnormal (clinically significant [CS])
             electrocardiogram (ECG).

          -  Has a supine blood pressure outside the ranges of 90 to 140 mm Hg for systolic and 60
             to 90 mm Hg for diastolic, confirmed with one repeat testing within a maximum of 5
             minutes, at the Screening Visit or Check-in (Day -1) Visit.

          -  Has a resting heart rate outside the range 50 to 100 bpm, confirmed with repeat
             testing within a maximum of 5 minutes, at the Screening Visit or Check-in (Day -1)
             Visit.

          -  Has a QT interval with Fridericia's correction method (QTcF) &gt;450 ms (males) or &gt;470
             ms (females) or PR outside the range of 120 to 220 ms, confirmed with one repeat
             testing within a maximum of 5 minutes, at the Screening Visit or Check-in (Day -1)
             Visit.

          -  Has abnormal Screening or Check-in (Day -1) laboratory values that suggest a CS
             underlying disease or subject with the following lab abnormalities: ALT and/or AST
             &gt;1.5 the upper limits of normal.

          -  Has a risk of suicide according to the investigator's clinical judgment (eg, per
             Columbia-Suicide Severity Rating Scale [C-SSRS]) or has made a suicide attempt in the
             previous 6 months.

          -  Has uncontrolled, CS neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic,
             gastrointestinal, urologic, immunologic, endocrine disease, or psychiatric disorder,
             or other abnormality, which may impact the ability of the subject to participate or
             potentially confound the study results.

          -  Has used nicotine-containing products (including but not limited to cigarettes,
             electronic cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum)
             within 28 days prior to Check-in (Day -1). Cotinine test is positive at Screening or
             Check-in (Day -1).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Austsitn</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2015</study_first_submitted>
  <study_first_submitted_qc>March 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <results_first_submitted>October 7, 2016</results_first_submitted>
  <results_first_submitted_qc>January 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2017</results_first_posted>
  <last_update_submitted>January 3, 2017</last_update_submitted>
  <last_update_submitted_qc>January 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in the United States from 20 February 2015 to 3 December 2015.</recruitment_details>
      <pre_assignment_details>Healthy non-elderly were enrolled in 1 of 5 treatment groups, TAK-058 25 mg, 75 mg, 150 mg, 300 mg or placebo. Healthy elderly participants were enrolled in 1 of 2 treatment groups, TAK-058 25 mg or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1 Non-elderly Healthy: TAK-058 25 mg</title>
          <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2 Non-elderly Healthy: TAK-058 75 mg</title>
          <description>TAK-058 75 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3 Non-elderly Healthy: TAK-058 150 mg</title>
          <description>TAK-058 150 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4 Elderly Healthy: TAK-058 25 mg</title>
          <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in elderly healthy participants.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 5 Non-elderly Healthy: TAK-058 300 mg</title>
          <description>TAK-058 300 mg solution, orally, once on Day 1, in non-elderly healthy participants.</description>
        </group>
        <group group_id="P6">
          <title>Cohorts 1, 2, 3 and 5 Non-elderly Healthy: Placebo</title>
          <description>TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10 (Cohorts 1, 2 and 3), or TAK-058 placebo-matching solution, orally, once on Day 1 (Cohort 5), in non-elderly healthy participants.</description>
        </group>
        <group group_id="P7">
          <title>Cohort 4 Elderly Healthy: Placebo</title>
          <description>TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Set, all enrolled participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1 Non-elderly Healthy: TAK-058 25 mg</title>
          <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2 Non-elderly Healthy: TAK-058 75 mg</title>
          <description>TAK-058 75 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3 Non-elderly Healthy: TAK-058 150 mg</title>
          <description>TAK-058 150 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 4 Elderly Healthy: TAK-058 25 mg</title>
          <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in elderly healthy participants.</description>
        </group>
        <group group_id="B5">
          <title>Cohort 5 Non-elderly Healthy: TAK-058 300 mg</title>
          <description>TAK-058 300 mg solution, orally, once on Day 1, in non-elderly healthy participants.</description>
        </group>
        <group group_id="B6">
          <title>Cohorts 1, 2, 3 and 5 Non-elderly Healthy: Placebo</title>
          <description>TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10 (Cohorts 1, 2 and 3), or TAK-058 placebo-matching solution, orally, once on Day 1 (Cohort 5), in non-elderly healthy participants.</description>
        </group>
        <group group_id="B7">
          <title>Cohort 4 Elderly Healthy: Placebo</title>
          <description>TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="8"/>
            <count group_id="B7" value="2"/>
            <count group_id="B8" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.3" spread="6.77"/>
                    <measurement group_id="B2" value="36.2" spread="11.65"/>
                    <measurement group_id="B3" value="42.2" spread="11.23"/>
                    <measurement group_id="B4" value="68.2" spread="1.83"/>
                    <measurement group_id="B5" value="41.0" spread="15.39"/>
                    <measurement group_id="B6" value="40.9" spread="13.67"/>
                    <measurement group_id="B7" value="72.5" spread="2.12"/>
                    <measurement group_id="B8" value="46.6" spread="15.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171.5" spread="10.17"/>
                    <measurement group_id="B2" value="171.0" spread="7.95"/>
                    <measurement group_id="B3" value="173.2" spread="10.23"/>
                    <measurement group_id="B4" value="173.7" spread="12.21"/>
                    <measurement group_id="B5" value="171.0" spread="9.42"/>
                    <measurement group_id="B6" value="176.1" spread="4.52"/>
                    <measurement group_id="B7" value="154.5" spread="2.12"/>
                    <measurement group_id="B8" value="172.0" spread="9.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.15" spread="9.291"/>
                    <measurement group_id="B2" value="75.63" spread="10.397"/>
                    <measurement group_id="B3" value="83.55" spread="12.902"/>
                    <measurement group_id="B4" value="83.08" spread="10.778"/>
                    <measurement group_id="B5" value="74.17" spread="15.687"/>
                    <measurement group_id="B6" value="79.63" spread="9.721"/>
                    <measurement group_id="B7" value="68.35" spread="5.869"/>
                    <measurement group_id="B8" value="78.23" spread="11.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.87" spread="1.742"/>
                    <measurement group_id="B2" value="25.80" spread="2.392"/>
                    <measurement group_id="B3" value="27.68" spread="1.451"/>
                    <measurement group_id="B4" value="27.48" spread="1.094"/>
                    <measurement group_id="B5" value="25.17" spread="3.463"/>
                    <measurement group_id="B6" value="25.66" spread="2.942"/>
                    <measurement group_id="B7" value="28.60" spread="1.697"/>
                    <measurement group_id="B8" value="26.36" spread="2.416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Never Smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Caffeine Consumption</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Consumption</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Never Drunk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Drinker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-drinker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Reproductive Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Postmenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgically Sterile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female of Childbearing Potential</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Applicable (Participant is Male)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event</title>
        <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.</description>
        <time_frame>Cohorts 1-4 Day 1 to Day 40; Cohort 5 Day 1 to Day 14</time_frame>
        <population>Safety Set, all enrolled participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 Non-elderly Healthy: TAK-058 25 mg</title>
            <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 Non-elderly Healthy: TAK-058 75 mg</title>
            <description>TAK-058 75 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 Non-elderly Healthy: TAK-058 150 mg</title>
            <description>TAK-058 150 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 Elderly Healthy: TAK-058 25 mg</title>
            <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in elderly healthy participants.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5 Non-elderly Healthy: TAK-058 300 mg</title>
            <description>TAK-058 300 mg solution, orally, once on Day 1, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O6">
            <title>Cohorts 1, 2, 3 and 5 Non-elderly Healthy: Placebo</title>
            <description>TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10 (Cohorts 1, 2 and 3), or TAK-058 placebo-matching solution, orally, once on Day 1 (Cohort 5), in non-elderly healthy participants.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 Elderly Healthy: Placebo</title>
            <description>TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event</title>
          <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.</description>
          <population>Safety Set, all enrolled participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="66.7"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post-Dose</title>
        <description>The percentage of participants with any markedly abnormal standard safety laboratory values (chemistry and hematology) collected throughout study.</description>
        <time_frame>Cohorts 1-4 Day 1 to Day 40; Cohort 5 Day 1 to Day 14</time_frame>
        <population>Safety Set, all enrolled participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 Non-elderly Healthy: TAK-058 25 mg</title>
            <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 Non-elderly Healthy: TAK-058 75 mg</title>
            <description>TAK-058 75 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 Non-elderly Healthy: TAK-058 150 mg</title>
            <description>TAK-058 150 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 Elderly Healthy: TAK-058 25 mg</title>
            <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in elderly healthy participants.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5 Non-elderly Healthy: TAK-058 300 mg</title>
            <description>TAK-058 300 mg solution, orally, once on Day 1, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O6">
            <title>Cohorts 1, 2, 3 and 5 Non-elderly Healthy: Placebo</title>
            <description>TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10 (Cohorts 1, 2 and 3), or TAK-058 placebo-matching solution, orally, once on Day 1 (Cohort 5), in non-elderly healthy participants.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 Elderly Healthy: Placebo</title>
            <description>TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post-Dose</title>
          <description>The percentage of participants with any markedly abnormal standard safety laboratory values (chemistry and hematology) collected throughout study.</description>
          <population>Safety Set, all enrolled participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="12.5"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Signs at Least Once Post-Dose</title>
        <description>The percentage of participants with any markedly abnormal standard vital sign values collected throughout study. Vital signs included blood pressure (after 5 minutes supine and at 1 and 3 minutes after standing), pulse and oral temperature.</description>
        <time_frame>Cohorts 1-4 Day 1 to Day 40; Cohort 5 Day 1 to Day 14</time_frame>
        <population>Safety Set, all enrolled participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 Non-elderly Healthy: TAK-058 25 mg</title>
            <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 Non-elderly Healthy: TAK-058 75 mg</title>
            <description>TAK-058 75 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 Non-elderly Healthy: TAK-058 150 mg</title>
            <description>TAK-058 150 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 Elderly Healthy: TAK-058 25 mg</title>
            <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in elderly healthy participants.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5 Non-elderly Healthy: TAK-058 300 mg</title>
            <description>TAK-058 300 mg solution, orally, once on Day 1, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O6">
            <title>Cohorts 1, 2, 3 and 5 Non-elderly Healthy: Placebo</title>
            <description>TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10 (Cohorts 1, 2 and 3), or TAK-058 placebo-matching solution, orally, once on Day 1 (Cohort 5), in non-elderly healthy participants.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 Elderly Healthy: Placebo</title>
            <description>TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Signs at Least Once Post-Dose</title>
          <description>The percentage of participants with any markedly abnormal standard vital sign values collected throughout study. Vital signs included blood pressure (after 5 minutes supine and at 1 and 3 minutes after standing), pulse and oral temperature.</description>
          <population>Safety Set, all enrolled participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Markedly Abnormal Vital Sign</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="50.0"/>
                    <measurement group_id="O6" value="12.5"/>
                    <measurement group_id="O7" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="12.5"/>
                    <measurement group_id="O7" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Cmax: Maximum Observed Plasma Concentration for TAK-058</title>
        <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
        <time_frame>Day 1 predose and at multiple time points (up to 72 hours) postdose, and Day 10 predose and at multiple time points (up to 24 hours) postdose</time_frame>
        <population>Pharmacokinetic Set, all participants who were in the safety set and had at least 1 measurable plasma concentration or amount of drug in urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 Non-elderly Healthy: TAK-058 25 mg</title>
            <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 Non-elderly Healthy: TAK-058 75 mg</title>
            <description>TAK-058 75 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 Non-elderly Healthy: TAK-058 150 mg</title>
            <description>TAK-058 150 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 Elderly Healthy: TAK-058 25 mg</title>
            <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in elderly healthy participants.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5 Non-elderly Healthy: TAK-058 300 mg</title>
            <description>TAK-058 300 mg solution, orally, once on Day 1, in non-elderly healthy participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cmax: Maximum Observed Plasma Concentration for TAK-058</title>
          <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
          <population>Pharmacokinetic Set, all participants who were in the safety set and had at least 1 measurable plasma concentration or amount of drug in urine.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1076.0" spread="272.66"/>
                    <measurement group_id="O2" value="2085.0" spread="492.70"/>
                    <measurement group_id="O3" value="2366.7" spread="738.88"/>
                    <measurement group_id="O4" value="811.8" spread="179.48"/>
                    <measurement group_id="O5" value="3361.7" spread="479.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1035.0" spread="404.58"/>
                    <measurement group_id="O2" value="2021.7" spread="577.91"/>
                    <measurement group_id="O3" value="2158.3" spread="560.69"/>
                    <measurement group_id="O4" value="886.2" spread="332.50"/>
                    <measurement group_id="O5" value="NA">This cohort received a single dose on Day 1 only, therefore Day 10 analysis not applicable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-058</title>
        <description>AUClast is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration.</description>
        <time_frame>Day 1 predose and at multiple time points (up to 72 hours) postdose</time_frame>
        <population>Pharmacokinetic Set, all participants who were in the safety set and had at least 1 measurable plasma concentration or amount of drug in urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 Non-elderly Healthy: TAK-058 25 mg</title>
            <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 Non-elderly Healthy: TAK-058 75 mg</title>
            <description>TAK-058 75 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 Non-elderly Healthy: TAK-058 150 mg</title>
            <description>TAK-058 150 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 Elderly Healthy: TAK-058 25 mg</title>
            <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in elderly healthy participants.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5 Non-elderly Healthy: TAK-058 300 mg</title>
            <description>TAK-058 300 mg solution, orally, once on Day 1, in non-elderly healthy participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-058</title>
          <description>AUClast is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration.</description>
          <population>Pharmacokinetic Set, all participants who were in the safety set and had at least 1 measurable plasma concentration or amount of drug in urine.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4414.6" spread="1461.59"/>
                    <measurement group_id="O2" value="9223.2" spread="5433.05"/>
                    <measurement group_id="O3" value="12262.6" spread="4671.88"/>
                    <measurement group_id="O4" value="4326.8" spread="1287.86"/>
                    <measurement group_id="O5" value="15143.1" spread="3471.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean AUC24: Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-058</title>
        <description>AUC24 is measure of area under the curve from time 0 to 24 hours postdose.</description>
        <time_frame>Day 1 predose and at multiple time points (up to 24 hours) postdose</time_frame>
        <population>Pharmacokinetic Set, all participants who were in the safety set and had at least 1 measurable plasma concentration or amount of drug in urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 Non-elderly Healthy: TAK-058 25 mg</title>
            <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 Non-elderly Healthy: TAK-058 75 mg</title>
            <description>TAK-058 75 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 Non-elderly Healthy: TAK-058 150 mg</title>
            <description>TAK-058 150 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 Elderly Healthy: TAK-058 25 mg</title>
            <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in elderly healthy participants.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5 Non-elderly Healthy: TAK-058 300 mg</title>
            <description>TAK-058 300 mg solution, orally, once on Day 1, in non-elderly healthy participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean AUC24: Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-058</title>
          <description>AUC24 is measure of area under the curve from time 0 to 24 hours postdose.</description>
          <population>Pharmacokinetic Set, all participants who were in the safety set and had at least 1 measurable plasma concentration or amount of drug in urine.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4372.6" spread="1436.73"/>
                    <measurement group_id="O2" value="8862.9" spread="4782.64"/>
                    <measurement group_id="O3" value="12013.0" spread="4495.56"/>
                    <measurement group_id="O4" value="4244.9" spread="1243.28"/>
                    <measurement group_id="O5" value="14852.3" spread="3348.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-058</title>
        <description>Area under the plasma concentration-time curve during a dosing interval, where tau (τ) is the length of the dosing interval.</description>
        <time_frame>Day 10 predose and at multiple time points (up to 24 hours) postdose</time_frame>
        <population>Pharmacokinetic Set, all participants who were in the safety set and had at least 1 measurable plasma concentration or amount of drug in urine.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 Non-elderly Healthy: TAK-058 25 mg</title>
            <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 Non-elderly Healthy: TAK-058 75 mg</title>
            <description>TAK-058 75 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 Non-elderly Healthy: TAK-058 150 mg</title>
            <description>TAK-058 150 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 Elderly Healthy: TAK-058 25 mg</title>
            <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in elderly healthy participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-058</title>
          <description>Area under the plasma concentration-time curve during a dosing interval, where tau (τ) is the length of the dosing interval.</description>
          <population>Pharmacokinetic Set, all participants who were in the safety set and had at least 1 measurable plasma concentration or amount of drug in urine.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4295.3" spread="2208.92"/>
                    <measurement group_id="O2" value="8325.4" spread="4642.29"/>
                    <measurement group_id="O3" value="11905.9" spread="4447.14"/>
                    <measurement group_id="O4" value="4539.2" spread="1509.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Collection of AEs commenced from the time that the participant was first administered study medication on Day 1 until 30 days following last dose (up to Day 40 for Cohorts 1-4 and up to Day 30 for Cohort 5).</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 Non-elderly Healthy: TAK-058 25 mg</title>
          <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2 Non-elderly Healthy: TAK-058 75 mg</title>
          <description>TAK-058 75 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3 Non-elderly Healthy: TAK-058 150 mg</title>
          <description>TAK-058 150 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 4 Elderly Healthy: TAK-058 25 mg</title>
          <description>TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in elderly healthy participants.</description>
        </group>
        <group group_id="E5">
          <title>Cohort 5 Non-elderly Healthy: TAK-058 300 mg</title>
          <description>TAK-058 300 mg solution, orally, once on Day 1, in non-elderly healthy participants.</description>
        </group>
        <group group_id="E6">
          <title>Cohorts 1, 2, 3 and 5 Non-elderly Healthy: Placebo</title>
          <description>TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10 (Cohorts 1, 2 and 3), or TAK-058 placebo-matching solution, orally, once on Day 1 (Cohort 5), in non-elderly healthy participants.</description>
        </group>
        <group group_id="E7">
          <title>Cohort 4 Elderly Healthy: Placebo</title>
          <description>TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version: 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Infrequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hypervigilance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda’s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

